CuraTeQ Biologics, a step-down subsidiary of Aurobindo Pharma, has obtained marketing approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for Bevqolva, its biosimilar to bevacizumab. Bevqolva Details Bevqolva is a 25 mg/mL concentrate for infusion, available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials. It is administered via …